638218-70-9 Usage
General Description
3-Benzofurancarboxylic acid, 6-hydroxy-2-methyl-, methyl ester is a chemical compound commonly known as esculetin, which is derived from natural sources such as the bark of the American and European white elm trees. It is a derivative of coumarin and has been investigated for its potential therapeutic effects, including anti-inflammatory, antioxidant, and anticancer properties. Esculetin is also used in some cosmetic and skincare products due to its potential skin lightening and anti-aging effects. However, further research is needed to fully understand its mechanisms of action and potential applications in the medical and cosmetic fields. Overall, esculetin is a compound of interest for its potential health benefits and applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 638218-70-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,8,2,1 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 638218-70:
(8*6)+(7*3)+(6*8)+(5*2)+(4*1)+(3*8)+(2*7)+(1*0)=169
169 % 10 = 9
So 638218-70-9 is a valid CAS Registry Number.
638218-70-9Relevant articles and documents
Novel and convenient synthesis of benzofurans from dihydrocoumarins
Shachan-Tov, Sharona,Frimer, Aryeh A.
, p. 905 - 908 (2012)
7-Hydroxy-3,4-dihydrocoumarin-4-carboxylic acid (7), conveniently prepared from m-resorcinol and maleic anhydride, was surprisingly transformed by acid anhydride and pyridine into the corresponding ketone, 4-alkanoyl analog 11. The latter reacted in turn
Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
-
, (2008/06/13)
The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
